Multiple cutaneous telangiectasias after the use of trastuzumab: a case report

We aim to report a particular case of cutaneous telangiectasias on the arms after immunotherapy with trastuzumab plus paclitaxel to treat breast cancer. New oncology therapies reflect a major advance in cancer treatment. They greatly increase survival; however, they still cause certain adverse cutaneous events that should be taken into account for their proper management.

Pityriasis rosea-like rash after COVID-19 vaccination with Oxford-AstraZeneca: a possible trigger?

Scholars around the world have dedicated themselves to developing an effective vaccine against SARS-CoV-2. However, vaccines have produced adverse effects in some patients. We report the case of a 44-year-old man who developed a pruritic papulosquamous rash on the trunk with a characteristic pattern known as Christmas tree after receiving the first dose of the Oxford-AstraZeneca COVID-19 vaccine, similar to pityriasis rosea (PR). He had no previous symptoms of viral infection and tested negative for neutralizing antibodies (enzyme immunoassay) against COVID-19. There are few reports in the literature about the relationship between the onset of cutaneous adverse reactions and the Oxford-AstraZeneca vaccine, therefore, the dissemination of this case is of paramount importance.

Comparação da qualidade de vida entre pacientes pediátricos com dermatite atópica e com outras dermatoses no sul do Brasil / Comparison of the quality of life between pediatric patients with atopic dermatitis and other dermatoses in southern Brazil

Introdução: Doenças dermatológicas podem influenciar o estado psicológico, as relações pessoais e as atividades diárias dos pacientes pediátricos (1,2). Uma avaliação cuidadosa desses pacientes é fundamental para investigar os impactos das dermatoses em suas vidas. O objetivo do estudo é comparar a qualidade de vida de pacientes pediátricos com dermatite atópica (DA) em relação aos pacientes com outras dermatoses em um centro de referência em dermatologia no sul do Brasil. Métodos: Estudo transversal, com amostra por conveniência entre pacientes de 4 a 16 anos, atendidos durante o período de 2018 a 2019 em um ambulatório de dermatologia. Aplicou-se questionário com variáveis sociodemográficas e o Escore de qualidade de vida em Dermatologia Infantil (CDLQI). Resultados: A amostra foi composta por 70 pacientes com média de idade de 9,36 anos. As principais dermatoses que compuseram o grupo de pacientes com outras dermatoses (41,4%) foram molusco contagioso, vitiligo e acne. Pacientes com DA apresentaram uma pior qualidade de vida (média CDLQI 7,41) comparados com os pacientes que apresentavam outras dermatoses (média CDLQI 4,41), sendo os domínios sono e tratamento responsáveis por essa diferença, apresentando valor médio do CDLQI de 1,12 e 0,76 respectivamente na DA, e 0,34 e 0,31 nas outras dermatoses. Conclusão: Crianças com DA apresentam pior qualidade de vida, particularmente em relação ao sono e a realização do seu tratamento, quando comparadas às crianças com outras dermatoses. É necessária uma abordagem multidisciplinar com suporte psicológico para garantir um adequado manejo e reduzir os prejuízos na qualidade de vida desses pacientes.

Introduction: Skin diseases can influence the psychological state, personal relationships and daily activities of pediatric patients (1,2). A careful assessment of these patients is essential to investigate the impacts of dermatoses on their lives. The study was designed to compare the quality of life of pediatric patients with atopic dermatitis (AD) in relation to patients with other dermatoses at a dermatology referral center in southern Brazil. Methods: A cross-sectional study, with a convenience sample among patients aged 4 to 16 years, treated during the period from 2018 to 2019 in a dermatology outpatient clinic. A questionnaire with sociodemographic variables and the Child Dermatology Quality of Life Index (CDLQI) were used. Results: The sample consisted of 70 patients with a mean age of 9.36 years. The main dermatoses that made up the group of patients with other dermatoses (41.4%) were molluscum contagiosum, vitiligo and acne. Patients with AD had a worse quality of life (mean CDLQI 7.41) compared to patients with other dermatoses (mean CDLQI 4.41), with sleep and treatment domains responsible for this difference, with mean CDLQI values of 1.12 and 0.76, respectively, in AD, and 0.34 and 0.31 in the other dermatoses. Conclusion: Children with AD have a worse quality of life, particularly in terms of sleep and treatment, as compared to children with other dermatoses. A multidisciplinary approach with psychological support is necessary to ensure adequate management and reduce the losses in these patients' quality of life.